Cartesian Therapeutics, Inc. Stock: price and insider trades · United States

Cartesian Therapeutics, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 25 filings, from 15 insiders.

The record shows 1 purchase on the open market worth €176k, made by 1 insider, against 3 sales worth €221k by 3 insiders. Netting one side against the other leaves €44k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 senior executive among the declarants. One trade stands out by size: a purchase of €176k from Barabe Timothy C, disclosed on 8 December 2025.

The last purchase on record was published on 8 December 2025, which is 314 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

With 25 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 24 purchases and 25 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.8 m USD and net income at -130.3 m USD.

Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.